| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0acc7fd312a68983fb8b9d120043467e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-689
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-689
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2016-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31debaa5abc3dd3775a5837141ad9485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_709b80bc02d182a6f93a4bf80c775013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fff2d1af6e37d507b366020f26dc82e7 |
| publicationDate |
2021-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11066711-B2 |
| titleOfInvention |
Biomarkers for predicting Clostridium difficile infection treatment outcome |
| abstract |
Provided herein are biomarkers that can be altered in the gut of a mammal having CDI. One or more biomarkers can be used to predict Clostridium difficile infection (CDI) treatment outcome (e.g., response to primary CDI treatment and/or risk of recurrence after primary CDI treatment) in a mammal (e.g., a human) having CDI. Methods for using one or more biomarkers can be used to predict response to primary CDI treatment in a mammal having CDI. Methods for using one or more biomarkers can be used to predict risk of recurrence in a mammal having CDI. Also provided are methods of treating CDI. |
| priorityDate |
2015-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |